B. Riley Estimates Novavax's Q1 Earnings (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX - Free Report) - Equities research analysts at B. Riley dropped their Q1 2025 earnings per share estimates for Novavax in a research note issued on Monday, March 3rd. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will post earnings of ($0.46) per share for the quarter, down from their prior forecast of ($0.38). The consensus estimate for Novavax's current full-year earnings is ($1.46) per share. B. Riley also issued estimates for Novavax's Q2 2025 earnings at $0.64 EPS, Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.48) EPS, FY2025 earnings at ($0.78) EPS, FY2026 earnings at $0.11 EPS, FY2027 earnings at $0.61 EPS, FY2028 earnings at $0.59 EPS and FY2029 earnings at $1.36 EPS.

NVAX has been the topic of a number of other reports. BTIG Research began coverage on Novavax in a research report on Friday, February 28th. They issued a "buy" rating and a $19.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $19.00 price target on shares of Novavax in a report on Tuesday, December 10th. Finally, TD Cowen raised shares of Novavax to a "hold" rating in a research report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $18.00.

Novavax Price Performance

NVAX traded up $0.47 on Wednesday, reaching $8.34. The company's stock had a trading volume of 5,070,652 shares, compared to its average volume of 8,084,745. Novavax has a 1 year low of $3.81 and a 1 year high of $23.86. The business's 50 day moving average is $8.46 and its 200 day moving average is $9.79. The stock has a market cap of $1.34 billion, a price-to-earnings ratio of -3.69, a price-to-earnings-growth ratio of 2.85 and a beta of 2.92.

Remove Ads

Novavax (NASDAQ:NVAX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.24. The firm had revenue of $88.31 million during the quarter, compared to analyst estimates of $85.48 million. During the same quarter in the prior year, the firm earned ($1.44) EPS.

Insider Activity

In other Novavax news, Director James F. Young sold 5,400 shares of Novavax stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total value of $43,200.00. Following the completion of the transaction, the director now directly owns 51,760 shares in the company, valued at $414,080. The trade was a 9.45 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Rachel K. King sold 4,150 shares of the company's stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $9.02, for a total value of $37,433.00. Following the transaction, the director now directly owns 14,770 shares of the company's stock, valued at $133,225.40. This trade represents a 21.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 14,150 shares of company stock valued at $119,641. Company insiders own 1.00% of the company's stock.

Hedge Funds Weigh In On Novavax

Institutional investors have recently modified their holdings of the company. Creative Planning grew its position in Novavax by 34.5% in the 3rd quarter. Creative Planning now owns 32,482 shares of the biopharmaceutical company's stock worth $410,000 after purchasing an additional 8,339 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Novavax by 38.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company's stock worth $77,000 after buying an additional 1,598 shares during the period. Wealth Enhancement Advisory Services LLC bought a new position in Novavax in the 3rd quarter worth approximately $214,000. Nisa Investment Advisors LLC increased its position in Novavax by 1,192.7% in the 3rd quarter. Nisa Investment Advisors LLC now owns 23,449 shares of the biopharmaceutical company's stock valued at $296,000 after acquiring an additional 21,635 shares during the period. Finally, US Bancorp DE boosted its position in Novavax by 3,538.8% during the 3rd quarter. US Bancorp DE now owns 12,299 shares of the biopharmaceutical company's stock worth $155,000 after acquiring an additional 11,961 shares during the period. Institutional investors own 53.04% of the company's stock.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.